Pharmafile Logo

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

November 11, 2024 |  

OPEN Health is excited to announce the upcoming presentation of a collection of research supported by its Scientific Buyout Program. This initiative empowers our team members to dedicate time toward innovative projects in HEOR and market access. We’re proud to invest in our team’s growth and scientific excellence.

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

London, Nov 11, 2024 — OPEN Health, a preeminent global provider of scientific communicationsHEOR and market accesspatient engagement, and consulting services, today announced the upcoming presentation of a collection of research supported by its Scientific Buyout Program. The Scientific Buyout Program initiative allows staff members to “buy out” time from their regular duties to engage in important scientific projects, including developing manuscripts, exploring new methodologies, conducting research, and preparing conference presentations.

“Our Scientific Buyout Program reflects our dedication to fostering a culture of scientific excellence and collaboration,” said Professor Ben van Hout, Scientific Founder, OPEN Health HEOR & Market Access. “By providing the opportunity to focus on self-chosen projects, we aim to enhance our contributions to the HEOR and market access fields while encouraging professional development within our team.”

The program runs in three rounds each year, with the first two rounds in 2024 already demonstrating significant participation and promising outcomes. In total, 83 scientists across OPEN Health submitted their project proposals, resulting in 26 projects shortlisted and presented to the Scientific Office. Ultimately, 65% of projects were accepted and funded, highlighting that the time allocation provided through the initiative further drives advanced research.

As a result, OPEN Health is proud to announce that 12 presentations will be made at two international conferences in 2024, including 9 posters at the prestigious ISPOR EU conference in Barcelona. The posters cover the key topics of the conference including the use and acceptability of AI in HTA, patient engagement in HTA, and EU HTA processes, among others, and will feature the “Funded by the Scientific Office” stamp, emphasizing the support behind these projects.

Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, added, “This program not only empowers our scientists but also fosters a collaborative environment where new ideas can thrive. We believe that investing in our scientific talent is crucial for driving progress in healthcare.”

For more information about the Scientific Buyout Program and OPEN Health’s commitment to scientific advancement, please visit https://www.openhealthgroup.com/what-we-do/heor-market-access/

 

About OPEN Health: OPEN Health unites world-class scientific, strategic, and creative expertise to solve complex challenges for global biopharma. We are a flexible, global organization, creating high-performing strategic partnerships with our clients. We embrace our different perspectives and strengths to deliver innovative solutions that have a positive impact on commercial and patient outcomes. OPEN Health unlocks possibilities across consulting, HEOR and market access, scientific communications, and patient engagement. To learn more, visit www.openhealthgroup.com.

Contact:

Candice Subero

OPEN Health

candicesubero@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health expands offering with the launch of a new Learning & Development specialist team

Enhanced expertise to deliver impactful internal training programmes for healthcare clients

Spotlight interview: 15 minutes on healthcare communications in gene therapy

Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy

OPEN Health becomes sponsor of MedComms Networking

New for 2020, OPEN Health is pleased to announce its sponsorship of MedComms Networking

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...